United Therapeutics Corp (UTHR) Stock Price
UTHRStock
$533.12+23.21%52W
Market Cap$22.87B
P/E17.13x
PEG Ratio2.22
Div yield—
Beta0.50
UTHR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.76%
Price vs S&P 500 (4W)9.44%
PEG Ratio2.22
VGM Score59.04
P/E Ratio (Annual)17.13x
UTHR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $6.86 | $7.27 | +5.95%(+$0.41) | |
| Q1 2026 | $6.86 | $5.82 | -15.13%(-$1.04) | |
| Q4 2025 | $6.76 | $7.70 | +13.99%(+$0.94) | |
| Q3 2025 | $6.96 | $7.16 | +2.86%(+$0.20) | |
| Q2 2025 | $6.94 | $6.41 | -7.65%(-$0.53) |
UTHR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
UTHRUnited Therapeutics Corp | C | C | B | 7.2x | 2.5% | 86.1% | 19.3% | $533.12 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About United Therapeutics Corp
United Therapeutics Corp develops and markets therapies for pulmonary arterial hypertension (PAH), a rare and progressive lung disease characterized by elevated blood pressure in the pulmonary arteries. The company's portfolio centers on treprostinil-based treatments, with Tyvaso DPI (inhalation powder) as its primary revenue driver, supported by Remodulin (injection), Orenitram (extended-release tablets), Adcirca (tadalafil), and Unituxin. The U.S. market generates the majority of revenue, though the company maintains a presence in international markets.